奥锐特药业股份有限公司（以下简称"公司"）已于 2025 年 8 月 29 日发布 公司 2025 年半年度报告，为便于广大投资者更全面深入地了解公司 2025 年半年 度的经营成果、财务状况，公司计划于 2025 年 09 月 15 日下午 14:00-14:45 举 行 2025 年半年度业绩说明会，就投资者关心的问题进行交流。 证券代码：605116 证券简称：奥锐特 公告编号：2025-061 债券代码：111021 债券简称：奥锐转债 奥锐特药业股份有限公司 关于召开 2025 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 投资者可于 2025 年 9 月 8 日（星期一）至 9 月 12 日（星期五）16:00 前登 录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 ir@aurisco. com 进行提问。公司将在说明会上对投资者普遍关注的问题进行回答。 四、投资者参加方式 一、说明会类型 本次投资者说明会以视频结合网络互动召开，公司将针对 2025 年半年度 ...

Core Insights - The company reported total assets of 3.903 billion yuan at the end of the reporting period, representing a 0.65% increase compared to the end of the previous year [1] - The net assets attributable to shareholders of the listed company reached 2.429 billion yuan, showing a year-on-year increase of 4.19% [1] - The operating revenue for the period was 822 million yuan, reflecting a year-on-year growth of 12.50% [1] - The total profit amounted to 268 million yuan, which is a 23.66% increase compared to the previous year [1] - The net profit attributable to shareholders of the listed company was 235 million yuan, marking a year-on-year increase of 24.55% [1] - The net cash flow from operating activities was 215 million yuan, up 28.71% year-on-year [1] - The top 10 shareholders include Zhejiang Tongben Investment Co., Ltd. and Chu Yizhou, holding 37.81% and 27.65% of shares respectively [1]

Group 1 - The company, Aorite (605116.SH), stated that it is currently not involved in any antibiotic-related business [1]

通过天眼查大数据分析，奥锐特药业股份有限公司共对外投资了10家企业，参与招投标项目58次，知识 产权方面有商标信息40条，专利信息76条，此外企业还拥有行政许可63个。 来源：金融界 奥锐特最新一期业绩显示，截至2025一季报，公司营业总收入4.02亿元、同比增长19.78%，归属净利润 1.19亿元，同比增长45.30%，扣非净利润1.13亿元，同比增长37.51%，流动比率4.618、速动比率 3.214、资产负债率37.37%。 天眼查商业履历信息显示，奥锐特药业股份有限公司，成立于1998年，位于台州市，是一家以从事医药 制造业为主的企业。企业注册资本40619.5万人民币，实缴资本40619.5万人民币。公司法定代表人为彭 志恩。 金融界消息 截至2025年8月19日收盘，奥锐特（605116）报收于25.03元，上涨4.55%，换手率4.17%， 成交量16.57万手，成交金额4.25亿元。 资金流向方面，今日主力资金净流入7522.44万元，占比成交额17.7%。其中，超大单净流入6474.49万 元、占成交额15.23%，大单净流入1047.95万元、占成交额2.47%，中单净流出流出2812 ...

Core Viewpoint - The weight loss drug sector is experiencing significant fluctuations, with several companies seeing substantial stock price increases [1] Company Summary - Boji Pharmaceutical (300404) and Ganli Pharmaceutical (603087) have reached their daily price limit increase [1] - Aorite (605116), Deyuan Pharmaceutical, and Meinuohua (603538) are also witnessing stock price increases, indicating a broader trend in the sector [1]

Core Insights - The report highlights the significant role of company secretaries (董秘) as a bridge between investors and listed companies, emphasizing their importance in capital operations within the A-share market [1] Salary Overview - The total salary for A-share company secretaries in 2024 reached 4.086 billion yuan, with an average annual salary of 754,300 yuan [1] - In the raw material pharmaceutical sector, the average annual salary for company secretaries is 608,400 yuan [1] Demographics - The age distribution shows that 60% of company secretaries are between 30-50 years old, while 38% are over 50, and only 2% are 30 or younger [1] - Educational background indicates that over 50% of company secretaries hold a bachelor's degree, with 9% having an associate degree, 39% holding a master's degree [1] Salary Distribution in Raw Material Pharmaceutical Sector - Among company secretaries in the raw material pharmaceutical sector, 49% earn below 500,000 yuan, 40% earn between 500,000 and 1 million yuan, and 11% earn over 1 million yuan [1] Top Earners - The top five highest-paid company secretaries are from Guobang Pharmaceutical, Saifen Technology, Keyuan Pharmaceutical, Aorite, and Zhejiang Pharmaceutical, with salaries ranging from 1.0832 million to 1.9309 million yuan [2] - The lowest-paid company secretaries earn below 200,000 yuan, with their salaries ranging from 174,200 to 190,700 yuan [2]

Core Viewpoint - The announcement details a share reduction plan by a senior executive of Aorite Pharmaceutical Co., Ltd. due to personal financial needs, involving a maximum reduction of 62,500 shares, which is 0.02% of the total share capital [2][3]. Group 1: Executive Shareholding Information - As of the announcement date, the total number of shares for Aorite Pharmaceutical is 406,195,234, with the executive Zhao Zhenping holding 250,000 shares, representing 0.06% of the total share capital [2]. Group 2: Reduction Plan Details - The executive plans to reduce shares through centralized bidding within three months after the announcement, starting 15 trading days later, with a maximum of 62,500 shares to be sold [3]. - The reduction will not exceed 25% of the executive's total shareholding, and any changes in share capital due to dividends or other corporate actions will adjust the reduction quantity accordingly [3]. Group 3: Other Relevant Information - The executive has no concerted actions with other shareholders and has made prior commitments regarding shareholding and reduction methods [4][6]. - The company will monitor the reduction plan and comply with relevant regulations, ensuring timely disclosure of any developments [9][17].

据统计，8月4日，盘后包括达意隆、山外山、开普检测、吉宏股份、红旗连锁、通达股份、神火股份、 康泰医学、步科股份、飞鹿股份、能辉科技、晶雪节能、胜宏科技、赛腾股份、雪迪龙、中芯国际、工 大高科、成都先导、飞乐音响、华电辽能、三维股份、奥锐特在内的22家A股上市公司披露减持情况。 当日暂无A股上市公司披露增持情况。 | 1 | 达意障 | 董事兼高级管理人员吴小满计划减持不超过4.22万股股份 | | --- | --- | --- | | 2 | 山外山 | 大健康和力远健鲲合计减持2.26%公司股份 | | 3 | 开普检测 | 副总经理贺春、张冉拟减持不超过0.54%公司股份 | | 4 | 吉宏股份 | 毒事长干亚朋计划减持不超过304万股 | | 5 | 红旗连锁 | 永辉超市拟减持不超过1%股份 | | 6 | 通达股份 | 控股股东拟减持不超过3%公司股份 | | 1 | 神火股份 | 普天工贸拟减持0.90%公司股份 | | 8 | 康泰医学 | 持股5%以上股东及部分董事、高管拟减持不超过3.59%股份 | | 9 | 步科股份 | 控股股东上海步进计划减持不超过3%公司股份 | | 10 | ...

（编辑 任世碧） 证券日报网讯 8月4日晚间，奥锐特发布公告称，截至2025年7月31日，公司通过上海证券交易所交易系 统以集中竞价交易方式已累计回购公司股份141.42万股，占公司目前总股本的比例为0.35%。 ...

Group 1 - Weihai Guangtai reported a net profit of 83.32 million yuan for the first half of 2025, a year-on-year decrease of 22.41%, while total revenue reached 1.425 billion yuan, an increase of 10.91% [1] - Haowei Group expects a net profit increase of 39.43% to 49.67% for the first half of 2025, estimating a profit range of 1.906 billion to 2.046 billion yuan [1] - Tengda Construction won a bid for a project worth 118 million yuan, with a construction period of 500 calendar days [1] Group 2 - Shanda Power plans to use up to 520 million yuan of idle raised funds for cash management, investing in safe and liquid products with a term not exceeding 12 months [3] - Rundu Co., Ltd. received approval for the listing application of its chemical raw material drug, which is suitable for surgical treatment in adults and children over one month old [4] - Zhongyuan Qihua's subsidiary's clinical trial application for a drug aimed at treating pulmonary fibrosis has been accepted [4] Group 3 - Shanghai Xiba plans to establish a joint venture with Yuyuan Rare Earth, focusing on advanced materials for lithium-ion solid-state batteries, with a registered capital of 200 million yuan [6] - Aorite's senior management plans to reduce their holdings by up to 62,500 shares, accounting for 0.02% of the company's total equity [7] - Yipin Hong's subsidiary's clinical trial application for a new oral drug for endometriosis has been accepted [8] Group 4 - Haya Pharmaceutical plans to lease idle assets covering 22,671.39 square meters for a period of 10 years [9] - Southern Precision Engineering applied for a credit limit of 50 million yuan from a bank for operational purposes [11] - Jindawei's subsidiary established a joint venture with a registered capital of 5 million yuan, focusing on the sale of food additives and health products [12] Group 5 - Gaode Infrared signed a product order contract worth 307 million yuan, expected to account for 11.46% of the company's audited revenue for 2024 [13] - Xichang Electric will implement a low valley electricity price policy starting September 1, 2025, which is expected to reduce net profit by approximately 5.55 million yuan [14] - Huyou Pharmaceutical's first subject has been dosed in a Phase I clinical trial for a drug targeting advanced solid tumors [16] Group 6 - Chuanheng Co., Ltd. received a patent for a dust removal system in mining operations [17] - Spring Wind Power's application for issuing convertible bonds has been accepted by the Shanghai Stock Exchange [18] - Liuyao Group plans to repurchase shares worth between 100 million and 200 million yuan [19] Group 7 - Baiyun Electric has obtained a commitment letter for a stock repurchase loan of up to 18 million yuan [20] - Tonghe Pharmaceutical received a patent for a method of preparing an intermediate for a migraine treatment drug [21] - Tainkang's subsidiary's Phase II clinical trial for a drug for vitiligo has shown significant efficacy and safety [23] Group 8 - Yuhua Tian's secretary and deputy general manager resigned for personal reasons [24] - Heizhima's controlling shareholder is planning a change in control, leading to a temporary suspension of stock trading [25] - Keda Li's subsidiary completed a capital increase, raising its registered capital to 700 million yuan [26] Group 9 - Fangda Special Steel's shareholder plans to reduce holdings by up to 1% of the company's shares [28] - ST Pava's director is under investigation for alleged embezzlement, but the company's operations remain normal [29] - Jiachuan Video's controlling shareholder is planning a change in control, resulting in a temporary stock suspension [32] Group 10 - Danhua Technology will change its stock name to Jinmei Technology starting August 7, 2025, due to a relocation of its registered office [33] - Morning Wind Technology's shareholder plans to reduce holdings by up to 1% of the company's shares [34] - Leshan Electric will adjust residential gas prices starting September 1, 2025, which is expected to increase gross profit by approximately 2.7 million yuan [35] Group 11 - SAIC Motor reported a total vehicle sales of 337,500 units in July 2025, a year-on-year increase of 34.22%, with significant growth in new energy vehicle sales [36] - LIGONG Navigation's shareholders plan to reduce holdings by up to 3% of the company's shares [37] - United Imaging's employee stock ownership platform plans to reduce holdings by up to 1.62% of the company's shares [38] Group 12 - Beiqi Blue Valley's subsidiary reported a 6.38% decline in sales in July 2025 [39] - Watson Bio's clinical research application for an mRNA vaccine has been accepted [40]